HANSOH PHARMA (03692): B7-H3 targeted antibody-drug conjugate HS-20093 for osteosarcoma included in breakthrough therapy.

Hansoh Pharma (03692) announced that on February 25, 2025, the company's self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection, HS-20093, has been approved by the National Medical Products Administration (NMPA) of China as a breakthrough therapy for the treatment of bone sarcoma patients who have progressed after at least second-line treatment. HS-20093 is a B7-H3 targeted ADC, consisting of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. It is currently undergoing multiple clinical studies in China for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors, with the highest stage of research being phase III clinical trials. As of November 1, 2024, the indication for HS-20093 in extensive-stage small cell lung cancer (ES-SCLC) that has progressed after standard first-line treatment (including platinum-based chemotherapy combined with immunotherapy) has been designated as a breakthrough therapy by the NMPA.